Publications by authors named "Marta Velasco Rodriguez-Belvis"
Background & Aims: The impact of biologic treatment for inflammatory bowel disease (IBD) during pregnancy and lactation on infant psychomotor development is barely studied. We investigated the effect of exposure to biologics in utero or during breastfeeding on the psychomotor development of offspring during their first year.
Methods: The study included patients and infants from DUMBO, an ongoing prospective, observational registry of GETECCU enrolling pregnant women (aged ≥18 years) with IBD from 60 centers across Spain.
The SARS-CoV-2 virus and its rapid spread have made it a global health concern. The aim of this was to investigate the microbial and metabolic faecal profiles of paediatric patients hospitalised for COVID-19 to try to identify biomarkers of predisposition to severity. The study included 16 patients (aged 4-14 years old) from six different Spanish hospitals and 20 age-matched healthy controls.
View Article and Find Full Text PDFFailure of anti-TNF therapy is a real concern in children with inflammatory bowel disease (IBD) owing to the limited therapeutic arsenal. Anti-TNF drugs modulate the immune response, a key driver of chronic inflammation in IBD. Accordingly, we analyzed changes in the frequency of T-lymphocyte and cytokine levels after 6 weeks of treatment to identify potential biomarkers of response to anti-TNF drugs.
View Article and Find Full Text PDFBackground: There are scarce data available on upadacitinib in children with Crohn's disease (CD).
Aim: To evaluate the effectiveness and safety of upadacitinib as an induction therapy in paediatric CD.
Methods: This was a multicentre retrospective study between 2022 and 2024 of children treated with upadacitinib for induction of remission of active CD conducted in 30 centres worldwide affiliated with the IBD Interest and Porto group of the ESPGHAN.
Background And Aims: Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as an induction therapy in pediatric UC or IBD-U.
Methods: In this multicenter retrospective study, children treated with upadacitinib for induction of remission of active UC or IBD-U from 30 centers worldwide were enrolled.
Impact of pediatric inflammatory bowel disease on caregivers' work productivity: A multicenter study by the SEGHNP.
J Pediatr Gastroenterol Nutr
September 2024
Article Synopsis
- Pediatric inflammatory bowel disease (PIBD) significantly affects family dynamics and caregiver work productivity, leading to economic strain on families.
- A multicenter study involving 370 parents of PIBD patients aged 10-18 revealed a 22.9% unemployment rate among caregivers, notably higher for mothers at 30.7%, with absenteeism and presenteeism further complicating work situations.
- The research highlights the need for targeted support and policy improvements to reduce the socioeconomic impact on families caring for children with PIBD.
Cross-cultural adaptation and validation of Work Productivity and Activity Impairment questionnaires for caregivers of patients with pediatric inflammatory bowel disease in Spain. A multicenter study.
Arch Argent Pediatr
December 2024
Article Synopsis
- The WPAI-UC/CD-Caregiver questionnaires evaluate how ulcerative colitis (UC) and Crohn's disease (CD) affect the work life and daily activities of caregivers in Spain.
- The study involved translating the questionnaires, getting feedback from experts and families, and validating them using data from 370 patients and their caregivers, ensuring they are effective and quick to complete.
- Results showed good reliability and validity of the Spanish versions of the questionnaires, making them suitable for use by families of children with inflammatory bowel disease (IBD).
Background And Objectives: Current data on ustekinumab therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBDU) are limited. We aimed to evaluate the effectiveness and safety of ustekinumab in pediatric UC and IBDU.
Methods: This multicenter retrospective study included 16 centers affiliated with the IBD Interest and Porto groups of ESPGHAN.
Unlabelled: IMPACT-III and IMPACT-III-P are health-related quality of life (HRQoL) questionnaires for patients with pediatric inflammatory bowel disease (p-IBD) and their parents/caregivers. We aimed to perform a transcultural adaptation and validation for the Spanish context. Translation, back-translation, and evaluation of the questionnaires were performed by an expert committee and 12 p-IBD families.
View Article and Find Full Text PDFUnlabelled: The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide, seriously endangering human health. Although SARS-CoV-2 had a lower impact on paediatric population, children with COVID-19 have been reported as suffering from gastrointestinal (GI) symptoms at a higher rate than adults. The aim of this work was to evaluate faeces as a source of potential biomarkers of severity in the paediatric population, with an emphasis on intestinal microbiota and faecal immune mediators, trying to identify possible dysbiosis and immune intestinal dysfunction associated with the risk of hospitalization.
View Article and Find Full Text PDF(1) Background: Transition is a planned movement of paediatric patients to adult healthcare systems, and its implementation is not yet established in all inflammatory bowel disease (IBD) units. The aim of the study was to evaluate the impact of transition on IBD outcomes. (2) Methods: Multicentre, retrospective and observational study of IBD paediatric patients transferred to an adult IBD unit between 2017-2020.
View Article and Find Full Text PDFSafety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
J Pediatr Gastroenterol Nutr
December 2022
Objectives: Escalation of the ustekinumab (UST) maintenance dosage was effective in adults with Crohn disease (CD), but no data are available for children. We evaluated the effectiveness and safety of dose escalation of UST in pediatric CD.
Methods: This was a retrospective multicenter study from 25 centers affiliated with the IBD Interest and Porto groups of ESPGHAN.
Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study.
Eur J Pediatr
September 2021
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Eur J Pediatr
September 2021
Article Synopsis
- Vedolizumab is a monoclonal antibody that targets integrin α4β7 on T-cells, preventing their migration to the gastrointestinal tract, and has been primarily used to treat inflammatory bowel disease in adults, though data on its use in children is limited.
- A study was conducted on 42 pediatric patients with inflammatory bowel disease who did not respond to previous anti-TNF therapies, evaluating the effectiveness and safety of vedolizumab for inducing and maintaining clinical remission.
- Results showed that at 14 weeks, 69% of patients responded to treatment and 52.4% achieved remission, with the response rates remaining high at 30 weeks, and most patients who achieved remission at week 14 maintained it at week
Article Synopsis
- A multicenter study involving 15 hospitals analyzed 101 pediatric patients hospitalized due to COVID-19, focusing on gastrointestinal (GI) symptoms.
- GI symptoms were found in 57% of the patients, with 14% experiencing them as the first sign of infection.
- Children with GI symptoms had an increased risk of requiring admission to the pediatric intensive care unit, indicating that these symptoms could predict the severity of COVID-19 in hospitalized kids.
The microbiota of our body is a rising issue on which more and more research is being studied and investigated. The acquisition and modification of the microbiota throughout life, and especially the alteration of its balance, is related to different diseases. One way to modify this microbiota, which can also be useful in disease situations, to restore the proper balance is through the consumption of marketed probiotics.
View Article and Find Full Text PDFBackground/objectives: The paediatric reference range of fecal calprotectin (FC) has not been decisively established and previous studies show a wide within-age variability, suggesting that other factors like anthropometric data or type of feeding can influence FC. Our aims were to establish the normal levels of FC in healthy children grouped by age and analyze whether sex, gestational age, birth weight, type of delivery, type of feeding, or anthropometric data influence FC values.
Methods: This multicentre, cross-sectional, and observational study enrolled healthy donors under 18 years of age who attended their Primary Health Care Centre for their routine Healthy Child Program visits.
Article Synopsis
- Exclusive enteral nutrition (EEN) is more effective than corticosteroids for achieving mucosal healing in children with Crohn's disease, without the negative side effects of steroids.
- A study covering 222 newly diagnosed pediatric patients found that 83% achieved clinical remission after an average of 8 weeks of EEN, with significant reductions in faecal calprotectin levels.
- Factors predicting a better response to EEN include specific scores on the Crohn's disease activity index, lower calprotectin levels, elevated CRP, and ileal involvement, suggesting EEN should be first-line treatment for pediatric Crohn's disease.
Prune belly syndrome.
Med Clin (Barc)
December 2020